CD163 and glioblastoma: Moreover, BLZ945 treatment enhances the initial response of GBM to radiotherapy (29) and improves the antitumor efficiency of anti–PD-1 (nivolumab) therapy by blocking CD163+ macrophage immunosuppressive polarization (77).